TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01971515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2363318A
Description: Part 1: MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression. Additional dose escalations will continue until Maximum Tolerated Dose (MTD) is reached, the food effect will be investigated in a separate group.~Part 2 (Cohort 1): MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression in subjects with PAM pathway alterations.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2363318A plus Trastuzumab
Description: Part 2 Cohort 2: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Trastuzumab.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Trastuzumab is a recombinant IgGI kappa humanized monoclonal antibody administered weekly by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2363318A plus Tamoxifen
Description: Part 2 Cohort 3: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Tamoxifen.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Tamoxifen is a nonsteroidal antiestrogen administered daily by oral administration.
Study: NCT03142776

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: periodontal debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photodynamic therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photodynamic therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic clarithromycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic clarithromycin
Study: NCT02557685

Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Translantation involves administering fecal material from a healthy donor to a sick patient, with relapsing C-difficile infection, to restore missing components of normal intestinal flora. Subjects will receive Fecal Microbiota Translantation via sigmoidoscopy.
Study: NCT02813902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heliocare with Fernblock PLE technology
Description: 240 mg taken orally daily over the course of 1 year

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: A pill that appears similar to the supplement
Study: NCT02114762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon dilation of the Eustachian tube
Description: Insert a balloon into one Eaustachian tube and inflate it for up to one minute. The balloon is then removed.
Study: NCT03563625

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: Caudal block/bupivacaine 0.25%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Local anesthetic wound infiltration/bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine
Study: NCT01159951

Intervention type: OTHER
Intervention: Epidemiologic Surveillance System of the Ministry of Health of Panama
Description: Systematic review of the databases of epidemiologic surveillance system, Ministry of health, Panama
Study: NCT04412525

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy (27G gauge or larger needle)
Description: vitrectomy surgery for either floater removal or macular surgery, with or without combined cataract (phaco) surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy (27G gauge or larger needle)
Description: vitrectomy surgery for either floater removal or macular surgery, with or without combined cataract (phaco) surgery.
Study: NCT00912210

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein isolate
Description: Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50g/day (two 25 g doses taken at breakfast and afternoon snack mixed with food or beverage)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin powder supplement
Description: Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50 g / day (two 25 g doses at breakfast and afternoon snack mixed with food or beverage)
Study: NCT02229578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
Study: NCT02034097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foretinib
Description: Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foretinib
Description: Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foretinib
Description: Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Round white tablet containing either 25 mg, 100 mg, or 150 mg of erlotinib will be orally administered in a dose level of 150 mg OD until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Round white tablet containing either 25 mg, 100 mg, or 150 mg of erlotinib will be orally administered in a dose level of 150 mg OD until disease progression
Study: NCT04830189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shoulder sling
Description: Patients were used shoulder slings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: forearm sling
Description: Patients were used forearm slings
Study: NCT04122209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIE-First
Description: Multiple exercise bout during the same day; HIIE first followed by continuous exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous-First
Description: Multiple exercise bout during the same day; Continuous exercise first followed by HIIE
Study: NCT01686867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Improved, ventilated cookstove
Description: An improved, ventilated cookstove incorporates the following key elements: burner openings customized to the size and shape of the cooking utensils; a flue designed to draw air into the fire box and pass it out through a chimney; a chimney, vented to the exterior, of adequate height to create a draft; an exterior port that has bidirectional openings to prevent the backflow of smoke and an access port for the chimney that permits cleaning.~The investigators piloted cookstoves prior to the trial and compared their ability to reduce indoor air pollution, the reliability between cookstoves of the same type, the functionality over time, preferences and cultural compatibility, and cost. The investigators selected the the Envirofit G-3300/3355, a modified Stovetec cookstove with a chimney and a locally-made improved, ventilated cookstove for use in the trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Improved, ventilated cookstove
Description: An improved, ventilated cookstove incorporates the following key elements: burner openings customized to the size and shape of the cooking utensils; a flue designed to draw air into the fire box and pass it out through a chimney; a chimney, vented to the exterior, of adequate height to create a draft; an exterior port that has bidirectional openings to prevent the backflow of smoke and an access port for the chimney that permits cleaning.~The investigators piloted cookstoves prior to the trial and compared their ability to reduce indoor air pollution, the reliability between cookstoves of the same type, the functionality over time, preferences and cultural compatibility, and cost. The investigators selected the the Envirofit G-3300/3355, a modified Stovetec cookstove with a chimney and a locally-made improved, ventilated cookstove for use in the trial.
Study: NCT03653767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Furniture
Description: The intervention will include adjustable school furniture.
Study: NCT03959761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) nivolumab infusion
Description: Patients will be treated according to three dose-levels of nivolumab, starting 5 to 7 days after surgery + Hyperthermic Intraperitoneal Chemotherapy (HIPEC), through an Intraperitoneal (IP) catheter :~* Level 1 : 0.5 milligrams/kilogram (mg/kg) IP infusion, repeated every 2 weeks for 4 infusions~* Level 2 : 1 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~* Level 3 : 3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~* Level -1 : 0,3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions
Study: NCT04648592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low salt diet plus sodium chloride supplements
Description: Patients will receive a low salt diet plus salt supplements.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low salt diet plus placebo
Description: Patients will receive a low salt diet plus placebo.
Study: NCT01615549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparsocopic cholecystectomy
Description: Perform laparsocopic cholecystectomy on a virtual reality devise

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparsocopic cholecystectomy
Description: Perform laparsocopic cholecystectomy on a virtual reality devise
Study: NCT01485497

Intervention type: DEVICE
Group type: OTHER
Intervention: 3D endoscopic Fourier Domain OCT
Description: Evaluation of Obstructive Sleep Apnea
Study: NCT04035980

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine based healthcare programme
Description: Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers
Study: NCT02038712

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fed Condition
Description: Subjects will consume a 600mL 600kcal liquid test meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fed Condition
Description: Subjects will consume a 600mL 600kcal liquid test meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasted condition
Description: Subjects will consume 600mL plain water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasted condition
Description: Subjects will consume 600mL plain water.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be collected at -15, 0, 10, 30, 60, 90, 120 min

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be collected at -15, 0, 10, 30, 60, 90, 120 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subjective appetite ratings
Description: Appetite ratings will be collected at -15, 0, 10, 30, 60, 90, 120 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subjective appetite ratings
Description: Appetite ratings will be collected at -15, 0, 10, 30, 60, 90, 120 min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI scan
Description: Blood Oxygen Dependent (BOLD) signal response to pictures and words of food and non-food items will be measured using functional magnetic resonance imaging (fMRI).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI scan
Description: Blood Oxygen Dependent (BOLD) signal response to pictures and words of food and non-food items will be measured using functional magnetic resonance imaging (fMRI).
Study: NCT04190576

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser Therapy
Description: Hydroxyapatite bone graft with collagen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Hydroxyapatite bone graft with collagen
Study: NCT05104255

Intervention type: PROCEDURE
Intervention: Spinal anesthesia
Description: Twins delivered under under spinal anesthesia

Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Twins delivered under general anesthesia
Study: NCT03510455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: BGJ398, a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor will be orally administered over six 4-week cycles (4 weeks on drug continuously). After the initial dose, escalation/de- escalation of BGJ398 will be based on FGF- 23 blood levels and adjusted according to protocol procedures. The six cycles of BGJ398 will be followed by 3 months off the drug and an optional extension phase.
Study: NCT01183039

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: 20 sessions of training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: 20 sessions of training
Study: NCT03090750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender Oil
Description: Lavender essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bergamot Oil
Description: Bergamot essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Tap water applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
Study: NCT03091816

Intervention type: DEVICE
Intervention: Computed Tomography Perfusion Imaging
Description: Undergo DPCT

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT02986945

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Resiliency App

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resiliency App
Study: NCT01560845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cells infusion （ABMSCi） plus abdominal portal hypertension surgery
Description: Immediately after the harvest of ABMSC, the modified Sugiura procedure was performed for the patients who were assigned to the study group. The time of ABMSC separation and purification was 2.5-3 hours which had to be completed before the conclusion of portal hypertension surgery (3-3.5 hours). ABMSC was infused into proper hepatic artery through right gastric artery during the portal hypertension surgery

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: open abdominal portal hypertension surgery
Description: the modified Sugiura procedure was performed for the patients
Study: NCT04560374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: crochet octopus
Description: Delivering crochet octopus to the hands of the neonates
Study: NCT00376415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lessertia Fructescens
Description: Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received an identical placebo capsule twice daily for 3 months.
Study: NCT02838979

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: First Intervention (14 days)
Description: Oral Glutamine or Maltodextrin for 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: First Intervention (14 days)
Description: Oral Glutamine or Maltodextrin for 2 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout (3 weeks)
Description: No study product is taken prior to beginning crossover

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout (3 weeks)
Description: No study product is taken prior to beginning crossover

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Second Intervention (14 days)
Description: Oral Glutamine or Maltodextrin for 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Second Intervention (14 days)
Description: Oral Glutamine or Maltodextrin for 2 weeks
Study: NCT01108315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Report symptoms via web or phone-based system
Description: The participant reports their symptoms at least twice a week via the phone or web-based prototype system.
Study: NCT00564616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video cell phone
Description: the voice group received voice CPR instruction via a voice-only cell phone, and the video group received interactive voice and video instruction via a video cell phone

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: video cell phone
Description: the voice group received voice CPR instruction via a voice-only cell phone, and the video group received interactive voice and video instruction via a video cell phone
Study: NCT03333161

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory monitoring
Description: We will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiorespiratory monitoring
Description: We will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations).
Study: NCT03653923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: Before the treatment, subjects will have one session of psychoeducation in which the rationale for the treatment is explained. In each therapy session subjects are exposed to 20 trials (each lasting 40s) of guided exposure by a psychotherapist. Further, 20 control trials of equal length are assessed in which subjects work with an earthworm. Each session lasts for approximately 90 minutes. During the therapy additional anxiety coping strategies (e.g., controlled breathing, attention refocusing, cognitive reappraisal) are trained.~Subjects of the waiting-list will be treated in the second study phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: Before the treatment, subjects will have one session of psychoeducation in which the rationale for the treatment is explained. In each therapy session subjects are exposed to 20 trials (each lasting 40s) of guided exposure by a psychotherapist. Further, 20 control trials of equal length are assessed in which subjects work with an earthworm. Each session lasts for approximately 90 minutes. During the therapy additional anxiety coping strategies (e.g., controlled breathing, attention refocusing, cognitive reappraisal) are trained.~Subjects of the waiting-list will be treated in the second study phase.
Study: NCT01967069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFD01 Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Spray
Study: NCT02410005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcitriol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Study: NCT02664597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADNEXMR Scoring System
Description: Patients will undergo a pelvic MR imaging (1.5T or 3T) as routinely performed, including morphological sequences (T2, T1 with and without fat suppression and T1 after dynamic gadolinium injection) and functional sequences (perfusion and diffusion-weighted sequences). Prospectively, a senior radiologist analyzes the different MR criteria to characterize adnexal masses. The reader will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard strategy
Description: In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.